Double-Stranded Nucleic Acids Inhibiting CFB Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement system-mediated diseases are limited, with only a subset of patients responding to existing therapies like Eculizumab, highlighting a need for more effective therapeutic strategies that target complement factor B (CFB) expression or activity.
Innovation Solution
Development of double-stranded nucleic acids that specifically inhibit CFB gene expression by mediating RNA interference, utilizing sequences that are complementary to CFB mRNA, thereby reducing CFB protein levels and mitigating associated disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies like Eculizumab are used to treat complement system-mediated diseases, then some patients can be treated, but only a subset of patients respond to the therapy
Solution Approach 1:
The patent employs siRNA molecules with specific sequence parameters (19 nucleotides complementary to CFB mRNA) and controlled structural parameters (double-stranded configuration with specific overhangs) to achieve reliable gene silencing. This molecular-level parameter optimization ensures consistent therapeutic efficacy across different patients by directly targeting CFB expression rather than relying on downstream complement inhibition
Solution Approach 2:
The invention extracts and targets the specific gene expression step (CFB mRNA translation) that drives complement factor B production, separating this upstream regulatory point from the downstream effects that existing therapies address. By extracting and inhibiting the specific mRNA translation step through siRNA, the therapy achieves broader patient applicability while maintaining reliable efficacy
2Ease of manufacture
If algorithms are used to design nucleic acid silencing triggers, then the design process is simplified, but the identified siRNAs may not be potent due to not accounting for tertiary structure and RNA binding proteins
Solution Approach 1:
The patent performs preliminary experimental validation of siRNA candidates against CFB mRNA before final selection, accounting for tertiary structure and RNA binding protein interactions in advance. This preliminary action ensures that only potent siRNAs with proven efficacy proceed to therapeutic development, resolving the contradiction between design simplicity and potency
Solution Approach 2:
The invention incorporates feedback mechanisms where siRNA performance is experimentally measured against CFB mRNA targets, and design parameters are adjusted based on observed potency and off-target effects. This iterative feedback process ensures high manufacturing precision while maintaining practical design feasibility
3Reliability
If siRNA molecules are developed to target CFB mRNA, then CFB expression can be inhibited, but the molecules must be synthesized economically, distributed to target tissues, enter cells and function within acceptable limits of toxicity
Solution Approach 1:
The patent employs lipid conjugates or protein conjugates as intermediary carriers that facilitate siRNA delivery to target tissues and cellular entry while protecting the siRNA from degradation. These intermediaries resolve the complexity of delivery by providing a standardized vehicle that can transport various siRNA sequences to their targets efficiently and safely
Solution Approach 2:
The invention optimizes siRNA parameters including sequence length (19 nucleotides), strand configuration (double-stranded with specific overhangs), and chemical modifications to balance synthesis feasibility, cellular uptake efficiency, and toxicity profiles. These parameter optimizations ensure reliable therapeutic efficacy while managing delivery complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed nucleic acid therapy effectively inhibits CFB expression, offering a promising approach for treating complement-mediated diseases by reducing inflammation and tissue damage associated with CFB overactivation.
Implementation Method 1
Double-stranded RNAs (dsRNA) able to bind through complementary base pairing to expressed mRNAs have been shown to block gene expression by a mechanism that has been termed 'RNA interference (RNAi)'
Implementation Method 2
Double-stranded RNAs (dsRNA) able to bind through complementary base pairing to expressed mRNAs
Implementation Method 3
RNAi is mediated by the RNA induced silencing complex (RISC), a sequence specific, multi component nuclease that degrades messenger RNAs having sufficient complementary or homology to the silencing trigger loaded into the RISC complex
Data Source
AI summary
The invention relates to nucleic acid products that interfere with complement factor B (CFB) gene expression or inhibit its expression. The nucleic acids are preferably for use in the prophylaxis or treatment of complement associated diseases, disorders or syndromes, particularly C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), lupus nephritis, IgA nephropathy (IgA N), myasthenia gravis (MG), and primary membranous nephropathy.